Javelin Pharmaceuticals, Inc. (JAV)

S&P 500: 890.35
Change: -2.13%

The Company is engaged in the research, development and commercialization of innovative treatments for the relief of moderate to severe pain.

Recs

Avatar ESTES27112 (37.51) Submitted: 5/16/08 5:01 PM : Start Price: $3.20 JAV Score: -17.58

This stock has been bludgeoned, but has now found and bottom and with 3 drugs in phase 3, this company could see profits within 2 years.

Featured Broker Partners